Date: 2015-03-25
Type of information: Collaboration agreement
Compound: TBX02
Company: Genvec (USA - MD) TheraBiologics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 23, 2015, GenVec announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology. In exchange for an economic participation in the products being developed under the collaboration, GenVec will contribute technology, know-how, vector construction, and technical and regulatory support to the program. TheraBiologics will be responsible for all other development costs. The initial goal of this collaboration is to generate a next-generation product candidate to TheraBiologics' TBX02. TBX02 utilizes an established NSC line engineered to express a modified carboxylesterase enzyme that converts the prodrug CPT-11 (Irinotecan) to the potent chemotherapy agent SN-38, which is 1000x more toxic to cancer cells than CPT-11. GenVec's proprietary adenovectors will be used to provide important manufacturing and potency advantages to other adenovirus-derived vectors and will utilize well-defined production methodologies that have already produced clinical trial material for over 3,000 study patients.
Financial terms:
Latest news:
